Navigation Links
Coronado Biosciences Closes $25.8M in Series C Financing
Date:7/6/2011

NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation.

Coronado plans to use the proceeds from the financing to advance its pipeline, including funding a Phase II study of the company's lead development candidate, CNDO-201 for the treatment of Crohn's Disease and a Phase I/II study of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML).  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs. CNDO-201 is also in development for other autoimmune diseases, including ulcerative colitis and multiple sclerosis.

CNDO-201 (Trichuris suis ova) is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines.  The use of porcine whipworm ova represents a novel approach and mechanism of action to treating autoimmune diseases that is based on the "hygiene hypothesis."  CNDO-201 has demonstrated meaningful clinical activity and a good safety profile in a three independent investigator sponsored clinical trials.  A Company sponsored Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease is scheduled for initiation in early 2012.  

CNDO-109 is a novel anti-cancer drug that primes natural killer (NK) cells without the need for cytokine (IL-2) treatment and shows significant potential for the treatment of hematological and solid tumors. CNDO-109 has produced impressive results in a Phase I clinical trial in patients with AML and demonstrated preclinical activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer.  Coronado plans to initiate a Phase I/II dose escalation and expansion trial in patients with relapsed AML in 2012. 
'/>"/>

SOURCE Coronado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
5. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
6. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
7. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
10. BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
11. Cell Biosciences Acquires Brightwell Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 1, 2015  An innovative interventional radiology treatment ... sustained relief of their headaches, according to research ... Radiology ,s Annual Scientific Meeting . Clinicians ... New York Empire State College in Saratoga Springs ... (SPG) blocks to give patients enough ongoing relief ...
(Date:3/1/2015)... 2015  USPlabs has notified the Food and ... that media reports saying that a company product ... February 28, 2015, the Center for Drug Evaluation ... the contamination of a dietary supplement product labeled ... as "OEP") with a prescription drug active ingredient, ...
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... the challenge of managing multiple products for the same ... especially for those that want to prevent one of ... of another.  According to recent research by ... promoted their products as independent brands rather than together ...
Breaking Medicine Technology:Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4OEP Product Is Counterfeit 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... 28, 2011 Hotspur Technologies announced today that ... first clinical use of its Keeper™ Embolectomy Catheter. ... formation within arteries, while also incorporating the capability ... catheter. The Keeper Catheter combines a ...
... ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" or ... and development outsourcing company, today announced that it will ... in New York from March 1 – 3, 2011. ... ShangPharma, will host a group presentation at 10:00 am ...
Cached Medicine Technology:Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011 2
(Date:3/1/2015)... 02, 2015 Security Life Insurance ... benefits market, announced the addition of stand-alone individual ... Vision Insurance launched today, complete with two plan ... utilize the VSP® Vision Care network encompassing a ... practice space. The PrimeStar Select Vision plan will ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 Researchers say working ... so many sheet metal workers contract malignant mesothelioma. Surviving ... report on its website. Click here to read ... Construction Research and Training monitored 17,345 sheet metal workers ... number of them died of mesothelioma or another ...
(Date:3/1/2015)... New York, NY (PRWEB) March 01, 2015 ... ) has grown substantially over the past few weeks ... Liebhard LLP are actively filing claims, the Firm announces. ... 2015 reflects 7,713 cases in the Bergen County proceeding ... Ethicon Inc., compared with a few weeks earlier, when ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
... The drilling and rasping necessary in cruciate ... roughness on the bone surface. This condition, ... can damage the cruciate replacement. The GORE ... cruciate ligament reconstruction procedures. The tool functions ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... has been designed by practicing neurophysiologists ... the ever changing and demanding medical ... data from multiple modalities, including: SSEPs ... multiple patients at multiple sites. Our ...
Medicine Products: